TIGIT / VSTM3 / VSIG9 (Immune Checkpoint for Cancer) (TIGIT/3106), 1mg/mL
TIGIT / VSTM3 / VSIG9 (Immune Checkpoint for Cancer) (TIGIT/3106), 1mg/mL thumbnail 1
GTR00925478

TIGIT / VSTM3 / VSIG9 (Immune Checkpoint for Cancer) (TIGIT/3106), 1mg/mL

casein-kinase-antibody

Description

TIGIT is a checkpoint inhibitor which binds with high affinity to the poliovirus receptor (PVR), causing increased IL10 secretion, decreased IL12B secretion. TIGIT binding to PVR also causes the suppression of T cell activation by promoting the generation of mature immuno-regulatory dendritic cells. It is expressed at low levels on natural killer (NK) cells, as well as peripheral memory and regulatory CD4 T cells. At the protein level, it is upregulated following the activation of these cells. Functionally, TIGIT is similar to CTLA4. The ligands for TIGIT include CD155 (signal abrogation) and CD226 (signal stimulation) . It has been demonstrated to be upregulated on T cells in many cancers and is a immuno-oncology target for therapy. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.

Specifications

Synonyms
T-cell immunoreceptor with Ig and ITIM domains; V-set and immunoglobulin domain containing 9 (VSIG9) ; V-set and transmembrane domain containing 3 (VSTM3) ; Washington University Cell Adhesion Molecule (WUCAM)

Description

TIGIT is a checkpoint inhibitor which binds with high affinity to the poliovirus receptor (PVR), causing increased IL10 secretion, decreased IL12B secretion. TIGIT binding to PVR also causes the suppression of T cell activation by promoting the generation of mature immuno-regulatory dendritic cells. It is expressed at low levels on natural killer (NK) cells, as well as peripheral memory and regulatory CD4 T cells. At the protein level, it is upregulated following the activation of these cells. Functionally, TIGIT is similar to CTLA4. The ligands for TIGIT include CD155 (signal abrogation) and CD226 (signal stimulation) . It has been demonstrated to be upregulated on T cells in many cancers and is a immuno-oncology target for therapy. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.

Specifications Table·product-specifications

Related Products

Thyroglobulin (Thyroidal Cell Marker) (TGB/1968R), CF568 conjugate, 0.1mg/mL
GTR00910265

Thyroglobulin (Thyroidal Cell Marker) (TGB/1968R), CF568 conjugate, 0.1mg/mL

1x 100 µL
$264.92($350.36)
Cathepsin D (Tumor Marker) (CTSD/3276), CF405S conjugate, 0.1mg/mL
GTR00915558

Cathepsin D (Tumor Marker) (CTSD/3276), CF405S conjugate, 0.1mg/mL

1x 500 µL
$645.08($853.12)
Human Papillomavirus 16 (HPV-16) (CAMVIR-1), 1mg/mL
GTR00925240

Human Papillomavirus 16 (HPV-16) (CAMVIR-1), 1mg/mL

1x 50 µL
$492.80($651.73)
Desmoglein-3 (Squamous Cell Marker) (DSG3/2837), CF405S conjugate, 0.1mg/mL
GTR00929079

Desmoglein-3 (Squamous Cell Marker) (DSG3/2837), CF405S conjugate, 0.1mg/mL

1x 500 µL
$645.08($853.12)